These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36119082)

  • 1. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review.
    Lai KC; Hsiao YH; Chen SC
    Front Immunol; 2022; 13():994064. PubMed ID: 36119082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
    Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
    Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
    Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
    Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
    Ogusu S; Harutani Y; Tozuka T; Saito R; Koyama J; Sakamoto H; Sonoda T; Tsuchiya-Kawano Y; Oba T; Kudo K; Gyotoku H; Nakatomi K; Ariyasu R
    Cancer Immunol Immunother; 2023 Nov; 72(11):3765-3772. PubMed ID: 37638979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
    Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
    Beattie J; Rizvi H; Fuentes P; Luo J; Schoenfeld A; Lin IH; Postow M; Callahan M; Voss MH; Shah NJ; Betof Warner A; Chawla M; Hellmann MD
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33568350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
    Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
    Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
    Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
    J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
    Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
    Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
    Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
    Horisberger A; La Rosa S; Zurcher JP; Zimmermann S; Spertini F; Coukos G; Obeid M
    J Immunother Cancer; 2018 Dec; 6(1):156. PubMed ID: 30587227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: a case report and review.
    Niimoto T; Todaka T; Kimura H; Suzuki S; Yoshino S; Hoashi K; Yamaguchi H
    Int J Emerg Med; 2024 Sep; 17(1):106. PubMed ID: 39223460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer.
    Tan P; Huang W; He X; Lv F; Cui Y; Du S
    J Immunother; 2023 Feb-Mar 01; 46(2):64-73. PubMed ID: 36637978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
    Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
    J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
    Yu H; Li J; Yu L; Cheng X; Han X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):519-525. PubMed ID: 34134189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitor-Related Pneumonitis.
    Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
    Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
    Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
    Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
    Balaji A; Verde F; Suresh K; Naidoo J
    Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.